Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (IT:1BMY)
:1BMY
1BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€37.78 - €59.13
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
$81.43B
Enterprise Value€131.71B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$50.93B
Price to Earnings (P/E)17.8
Beta0.30
Next Earnings
Oct 30, 2025EPS Estimate
1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding2,035,435,800
10 Day Avg. Volume37
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.62
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda8.73
Forecast
1Y Price Target
$43.52Price Target Upside9.09% Upside
Rating ConsensusHold
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Operational EfficiencyBristol is making solid progress with a $1 billion reduction in OPEX this year and clear reallocation in the pipeline.
Product DifferentiationCardiac myosin inhibitors should be used ahead of beta blockers in obstructive hypertrophic cardiomyopathy patients, which could favor uptake in certain patient populations.
Revenue GuidanceGuidance for FY25 revenue was raised by $700 million, indicating strong future performance expectations.
Bears Say
Clinical Trial UncertaintyAwaiting additional details on the labeling and REMS protocol to determine the near-term impact on Camzyos uptake, indicating uncertainty about its market performance.
Market Position ChallengesThere will be several updates in the cardiac myosin inhibitor space that will impact market share dynamics for Camzyos, potentially challenging its position.
Revenue ExpectationsCobenfy scripts are expected to miss Visible Alpha consensus estimates for 3Q25 revenue.
Bristol-Myers Squibb News
1BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €37.78 and its highest was €59.13 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $81.43B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Aug 01, 2025. The company reported €1.246 earnings per share for the quarter, beating the consensus estimate of €0.931 by €0.315.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb does not currently pay dividends.
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.44.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,435,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.246 in its last earnings report, beating expectations of €0.931. Following the earnings report the stock price went down -1.236%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in IT:1BMY
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.52 (9.09% Upside)
$43.52 (9.09% Upside)
Blogger Sentiment
Bullish
IT:1BMY Sentiment 88%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.14%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
1BMY Company Deck
1BMY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the growth portfolio and successful strategic initiatives, with increased revenue and earnings guidance. Despite challenges in the legacy portfolio and some study outcomes not meeting expectations, the company is well-positioned for long-term growth with a robust pipeline and strategic partnerships.View all IT:1BMY earnings summaries1BMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
1BMY Stock 12 Month Forecast
Average Price Target
€43.52
▲(9.09% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
23.12%
Mutual Funds
15.96% Other Institutional Investors
35.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---